|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Caveolin-1,E-cadherin and β-catenin in Gastric Carcinoma,Precancerous Tissues and Chronic Non-atrophic Gastritis显示文摘Objective:To investigate the expressions of caveolin-1,E-cadherin and β-catenin in gastric carcinoma,precancerous gastric and chronic non-atrophic gastritis tissues,and evaluate the correlation of these expressions with the development of gastric cancer.Methods:The expressions of caveolin-1,E-cadherin and β-catenin were detected by biotin-streptavidin-peroxidase(SP) immunohistochemistry on 58 gastric cancer tissues,40 precancerous gastric tissues and 42 chronic non-atrophic gastritis tissues.The correlation between the expressions of caveolin-1,E-cadherin and β-catenin,and the clinicopathologic parameters of gastric cancer was analyzed retrospectively.Results:The positive rates of caveolin-1 and E-cadherin expressions in gastric carcinoma were significantly lower than precancerous gastric and chronic non-atrophic gastritis tissues(P<0.01).An abnormal rate of β-catenin expression in gastric carcinoma was higher than precancerous gastric and chronic non-atrophic gastritis tissues(P<0.01).Moreover,low expressions of caveolin-1,E-cadherin and β-catenin correlated with tumor size,depth of invasion,lymph node metastasis and TNM stage(P<0.05).The positive rates of caveolin-1 and E-cadherin expressions decreased(P<0.01),while an abnormal rate of β-catenin expression increased inversely,with the degree of atypical hyperplasia(P<0.01).Caveolin-1 expression correlated positively with E-cadherin(r=0.41,P<0.05).Caveolin-1(r= 0.36,P<0.05) and E-cadherin(r= 0.45,P<0.05) expressions negatively correlated with abnormal β-catenin expression.Conclusion: These results suggested that dysregulated expressions of caveolin‐1, E‐cadherin and β‐catenin correlated with the development of gastric cancer and its biological behavior. | Guo-yang Sun Jun-xia Wu Jian-sheng Wu Yu-ting Pan Rong Jin | 2012 | Chinese Journal of Cancer Research2012，24，1： | 30 |
| 2 | Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients显示文摘AIM:To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal ad- enocarcinoma. METHODS:Methylation-specific polymerase chain reac- tion (MSPCR) was used to examine the promoter meth- ylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal dis- ease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls. Apaired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postopera- tive serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent sur- gical therapy. RESULTS:The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01). The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples. The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level. Although the serum RASSF1A promoter hypermethylation frequency tended to be higher in patients with distant metastases, there was no correlation between methylation status and metastasis. CONCLUSION:Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomark- er for gastric and colorectal cancer. | Yu-Cai Wang Zheng-HongYu Chang Liu Li-Zhi Xu Wen Yu Jia Lu Ren-Min Zhu Guo-Li Li Xin-Yi Xia Xiao-Wei Wei Hong-Zan Ji Heng Lu Yong Gao Wei-Min Gao Long-Bang Chen | 2008 | World Journal of Gastroenterology2008，14，19： | 26 |
| 3 | Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer显示文摘AIM:To investigate human epidermal growth factor receptor 2(HER2)-phosphatidylinositol 3-kinase(PI3K)-vAkt murine thymoma viral oncogene homolog signaling pathway.METHODS:We analyzed 231 formalin-fixed,paraffinembedded gastric cancer tissue specimens from Japanese patients who had undergone surgical treatment.The patients' age,sex,tumor location,depth of invasion,pathological type,lymph node metastasis,and pathological stage were determined by a review of the medical records.Expression of HER2 was analyzed by immunohistochemistry(IHC) using the HercepTest TM kit.Standard criteria for HER2 positivity(0,1+,2+,and 3+) were used.Tumors that scored 3+ were considered HER2-positive.Expression of phospho Akt(pAkt) was also analyzed by IHC.Tumors were considered pAkt-positive when the percentage of positive tumor cells was 10% or more.PI3K,catalytic,alpha polypeptide(PIK3CA) mutations in exons 1,9 and 20 were analyzed by pyrosequencing.Epstein-Barr virus(EBV) infection was analyzed by in situ hybridization targeting EBV-encoded small RNA(EBER) with an EBER-RNA probe.Microsatellite instability(MSI) was analyzed by polymerase chain reaction using the mononucleotide markers BAT25 and BAT26.RESULTS:HER2 expression levels of 0,1+,2+ and 3+ were found in 167(72%),32(14%),12(5%) and 20(8.7%) samples,respectively.HER2 overexpression(IHC 3+) significantly correlated with intestinal histological type(15/20 vs 98 /205,P = 0.05).PIK3CA mutations were present in 20 cases(8.7%) and significantly correlated with MSI(10/20 vs 9/211,P < 0.01).The mutation frequency was high(21%) in T4 cancers and very low(6%) in T2 cancers.Mutations in exons 1,9 and 20 were detected in 5(2%),9(4%) and 7(3%) cases,respectively.Two new types of PIK3CA mutation,R88Q and R108H,were found in exon1.All PIK3CA mutations were heterozygous missense singlebase substitutions,the most common being H1047R(6/20,30%) in exon20.Eighteen cancers(8%) were EBV-positive and this positivity significantly correlated with a diffuse histological type(13/18 vs 93/198,P = 0.04).There were 7 cases of lymphoepithelioma-like carcinomas(LELC) and 6 of those cases were EBV-positive(percent/EBV:6/18,33%;percent/all LELC:6/7,86%).pAkt expression was positive in 119(53%) cases but showed no correlation with clinicopathological characteristics.pAkt expression was significantly correlated with HER2 overexpression(16/20 vs 103/211,P < 0.01) but not with PIK3CA mutations(12/20 vs 107/211,P = 0.37) or EBV infection(8/18 vs 103/211,P = 0.69).The frequency of pAkt expression was higher in cancers with exon20 mutations(100%) than in those with exon1(40%) or exon9(56%) mutations.One case showed both HER2 overexpression and EBV infection and 3 cases showed both PIK3CA mutations and EBV infection.However,no cases showed both PIK3CA mutations and HER2 overexpression.One EBVpositive cancer with PIK3CA mutation(H1047R) was MSI-positive.Three of these 4 cases were positive for pAkt expression.In survival analysis,pAkt expression significantly correlated with a poor prognosis(hazard ratio 1.75;95%CI:1.12-2.80,P = 0.02).CONCLUSION:HER2 expression,PIK3CA mutations and EBV infection in gastric cancer were characterized.pAkt expression significantly correlates with HER2 expression and with a poor prognosis. | Yasutaka Sukawa Hiroyuki Yamamoto Katsuhiko Nosho Hiroaki Kunimoto Hiromu Suzuki Yasushi Adachi Mayumi Nakazawa Takayuki Nobuoka Mariko Kawayama Masashi Mikami Takashi Matsuno Tadashi Hasegawa Koichi Hirata Kohzoh Imai Yasuhisa Shinomura | 2012 | World Journal of Gastroenterology2012，18，45： | 19 |
| 4 | Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance显示文摘AIM: To evaluate the relation of cluster of differentiation 44 (CD44) expression with clinicopathological features of gastric adenocarcinoma, and also its effect on prognosis with an emphasis on the differences between intestinal and diffuse types. METHODS: From 2000 to 2006, 100 patients with gastric adenocarcinoma, who had undergone total or subtotal gastrectomy without any prior treatment, were studied. Haematoxylin & eosin (HE) staining was used for histological evaluation, including the type (Lauren's classifi cation) and grading of the tumor. The expression of CD44 in the gastric adenocarcinoma mucosa and the adjacent mucosa were determined by immunohistochemistry. The survival analysis was obtained using the Kaplan-Meier test. RESULTS: Of 100 patients, 74 (74%) patients were male. The tumors were categorized as intestinal type (78%) or diffuse type (22%). Sixty-five percent of patients were CD44-positive. CD44 expression was not detected in normal gastric mucosa. Rather, CD44 was more commonly expressed in the intestinal subtype (P = 0.002). A signifi cant relation was seen between the grade of tumor and the expression of CD44 (P = 0.014). The survival analysis showed a poor prognosis of patients with CD44-positive tumors (P = 0.008); and this was more prominent in the intestinal (P = 0.001) rather than diffuse type. CONCLUSION: Cell adhesion molecule CD44 is highly expressed in gastric adenocarcinoma. CD44 expression is correlated with a poor prognosis in patients with the intestinal type of gastric adenocarcinoma. CD44 can, therefore, be utilized as a prognostic marker for this group of patients. | Kamran Ghaffarzadehgan Mostafa Jafarzadeh Hamid Reza Raziee Hamid Reza Sima Ehsan Esmaili-Shandiz Hanieh Hosseinnezhad Ali Taghizadeh Kermani Omeed Moaven Maryam Bahrani | 2008 | World Journal of Gastroenterology2008，14，41： | 18 |
| 5 | 胃癌及癌前病变中PTEN及微卫星不稳定的变化及二者的关系显示文摘目的:探讨胃癌及癌前病变中抑癌基因PTEN和微卫星不稳定(MSI)的变化以及二者的关系.方法:胃癌及癌前病变标本取自中国医科大学附属第一医院内窥镜中心和肿瘤外科手术后,每组30例,PTEN杂合性缺失(LOH)和MS应用PCR-SSCP银染色方法检测,PTEN基因突变通过PCR-SSCPABI测序方法检测,S-P免疫组化检测PTEN蛋白质表达.结果:在萎缩性胃炎无肠化、萎缩性胃炎伴肠化、不典型增生、早期胃癌、进展期胃癌中PTENLOH率和MSI率分别为10%、10%、13.3%、20%、30%和13.3%、16.7%、23.3%、36%、40%.PTEN蛋白质表达在正常胃黏膜为100%,在慢性浅表性胃炎、慢性萎缩性胃炎无肠化、慢性萎缩性胃炎伴肠化、中度不典型增生、重度不典型增生、早期胃癌、进展期胃癌中PTEN蛋白质的表达分别为96.7%、90.0%、76.7%、73.3%、63.3%、60.0%、43.3%.所有病例共检测到3例PTEN突变,这3例均为MSI阳性的进展期胃癌.结论:PTEN缺失及突变与胃癌的浸润转移关系密切,在胃癌的发病过程中,PTEN蛋白呈下调性表达,MSI是胃癌发生的早期分子标志PTEN基因突变常发生在MSI阳性的进展期胃癌中. | 李异玲 田忠 傅宝玉 | 2008 | 世界华人消化杂志2008，16，22： | 17 |
| 6 | PTEN信号途径与肿瘤相关研究进展显示文摘PTEN是一种抑癌基因表达蛋白,具有双特异性磷酸酶活性,参与多种信号途径的调节。PTEN活性的缺失与人类多种疾病相关,特别是在肿瘤的发生上极为常见。近年来,研究人员对PTEN的研究主要集中在自身的转录调控和不依赖于PIP3激酶的信号途径上。本文就PTEN在信号途径及其与肿瘤相关中的研究进行综述。 | 曾今诚 林观平 周克元 | 2010 | 广东医学院学报2010，28，2： | 15 |
| 7 | 胃癌组织runt相关转录因子3基因表达与其甲基化状态的关系显示文摘目的探讨胃癌组织中DNA甲基化调控机制对runt相关转录因子3(Runx3)基因表达的影响。方法采用逆转录聚合酶链反应(RT-PCR)法检测70例胃癌组织及其配对的正常胃黏膜组织中Runx3mRNA表达,Westenblot法检测Runx3蛋白表达,甲基化特异性PCR(MSP)法检测Runx3基因启动子的甲基化状态;应用RT-PCR法检测DNA甲基转移酶1(Dnmtl)mRNA表达,分析Runx3基因甲基化与Dnmt1 mRNA表达之间的相关性。结果胃癌组织中Runx3mRNA表达(0.5740±0.3580)明显低于其配对的正常胃黏膜组织(1.7250±0.4080,P〈0.05),胃癌组织Runx3蛋白表达亦明显低于其配对的正常胃黏膜组织(P〈0.05)。在Runx3 mRNA表达下调的56例胃癌组织中,有28例(50.0%)呈启动子高甲基化状态。胃癌组织中,Runx3甲基化阳性者的Dnmt1 mRNA表达量明显高于Runx3甲基化阴性者(P〈0.05),Runx3基因启动子甲基化与Dnmt1转录表达呈正相关(r=0.64,P〈0.05)。结论Runx3基因启动子高甲基化是其基因表达下调的原因之一,可能参与胃癌的发生发展;Dnmt1高表达可能影响Runx3启动子区域甲基化改变。 | 高楠 陈卫昌 岑建农 | 2008 | 中华肿瘤杂志2008，30，5： | 15 |
| 8 | p53和c-erbB-2与胃癌关系的研究进展显示文摘目的介绍近年来抑癌基因p53和癌基因c-erbB-2与胃癌关系的研究进展。方法收集近年来国内、外关于胃癌中p53和c-erbB-2的相关文献并进行综述。结果 p53基因突变和c-erbB-2的过表达是胃癌发生中的常见事件。p53突变与胃癌的发生部位及其侵袭性生物学行为有关;c-erbB-2的过表达可作为判断胃癌预后的独立参数。针对p53及c-erbB-2的基因靶向治疗药物也在不断研究中。结论深入研究p53与c-erbB-2基因在胃癌发生、发展中的作用,将有助于清楚地认识胃癌的生物学行为,并为胃癌的基因治疗提供理论依据。 | 王宏波 纪常生 张军 | 2010 | 中国普外基础与临床杂志2010，17，8： | 14 |
| 9 | p53和NF-κB与胃癌的研究进展显示文摘目的:总结近年来国内外关于p53、NF-κB与胃癌发生发展关系的研究及其成为生物治疗靶点新进展。方法:应用PubMed及CNKI全文数据库,以胃癌、p53和NF-κB等关键词检索2005-01-2009-02相关文献,文献纳入标准:1)p53、NF-κB基因结构与功能;2)p53、NF-κB分别在胃癌中表达的研究;3)p53、NF-κB为生物靶点的药物研究及临床应用;4)p53和NF-κB在肿瘤中表达关系。粗选96篇相关文献,精选21篇纳入分析。结果:1)胃腺癌根据部位分类,p53阳性表达率观点不同。有研究提示,与部位无关,胃窦/胃角、胃底/胃体表达率分别为58.8%、47.6%,两者差异无统计学意义,P>0.05;另有研究结果则相反,结果贲门高于幽门(56%vs31.3%,χ2=5.03,P=0.025)。2)慢性炎症因子TNF存在时,突发型p53促进NF-κB活性。结论:突变型p53和NF-κBp65在肿瘤中表达可能存在协调表达现象。 | 杨晓艳 陈春华 苏秀兰 | 2010 | 中华肿瘤防治杂志2010，17，5： | 12 |
| 10 | Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers显示文摘AIM: To clarify the expression and role of Ephrin receptor A4 (EphA4) in gastric cancer in relation to clinicopathological characteristics and the expression of fibroblast growth factor receptor 1 (FGFR1) and ephrin ligands. METHODS: Eleven gastric carcinoma cell lines, 24 paired surgical fresh specimens of gastric adenocarcinoma and adjacent nontumor tissue, 74 conventional formalin-fixed, paraffin-embedded tumor specimens, and 55 specimens spotted on tissue microarray (TMA) were analyzed. Reverse transcription-PCR (RT-PCR), real-time RT-PCR, immunohistochemistry, and cell growth assays were performed. RESULTS: Overexpression of EphA4 mRNA expres-sion was observed in 8 (73%) of 11 gastric cancer cell lines and 10 (42%) of 24 gastric cancer tissues. Over-expression of EphA4, analyzed by immunohistochemistry, was observed in 62 (48%) of 129 gastric cancer tissues. EphA4 overexpression, at the protein level, was significantly associated with depth of invasion and recurrence. EphA4 overexpression was also correlated with FGFR1 overexpression. Patients with EphA4-positive cancer had significantly shorter overall survival periods than did those with EphA4-negative cancer (P = 0.0008). The mRNAs for ephrin ligands were coexpressed in various combinations in gastric cancer cell lines and cancer tissues. Downregulation of EphA4 expression by siRNA in EphA4-overexpressing gastric cancer cell lines resulted in a significant decrease in cell growth. CONCLUSION: Our results suggest that overexpres-sion of EphA4 plays a role in gastric cancer. | Mariko Oki Hiroyuki Yamamoto Hiroaki Taniguchi Yasushi Adachi Kohzoh Imai Yasuhisa Shinomura | 2008 | World Journal of Gastroenterology2008，14，37： | 11 |
| 11 | 慢性萎缩性胃炎黏膜上皮中P53和C-erbB-2表达的临床意义显示文摘目的:探讨慢性萎缩性胃炎(CAG)黏膜上皮中P53及C-erbB-2的表达及意义.方法:用免疫组化技术(SP法)检测正常胃黏膜56例、慢性萎缩性胃炎429例(腺体囊性扩张61例,大肠型化生73例,轻、中、重度不典型增生各120、91和84例)和早期胃癌57例中P53和C-erbB-2的表达,分析P53和C-erbB-2表达及其与CAG胃黏膜病变类型的关系.结果:正常胃黏膜,囊性扩张腺体,轻、中度不典型增生,大肠型化生,重度不典型增生,早期胃癌P53和C-erbB-2表达的阳性率呈上升趋势.前三组间表达率差异无统计学意义(P>0.05);正常胃黏膜与中度不典型增生、大肠型化生、重度不典型增生及胃癌组P53和C-erbB-2的表达差异有统计学意义(P<0.01).Spearman等级相关分析显示P53和C-efbB-2表达呈正相关(r=0.867,P<0.05).年龄<40岁和≥40岁组间、性别组间P53表达阳性率差异有统计学意义(x2=12.393,P<0.01;x2=8.799, P<0.01).C-erbB-2的表达在上述年龄组间差异有统计学意义(x2=7.706,P<0.01),而在性别组间无统计学意义(P>0.05).结论:检测慢性萎缩性胃炎中P53和C-erbB-2的表达,有助于监测CAG癌前病变的进展及胃癌的早期发现. | 赵松 付英梅 赵柏 刘连新 | 2006 | 世界华人消化杂志2006，14，30： | 10 |
| 12 | Survivin、Dnmt和CD44在胃溃疡及胃癌中表达的差异显示文摘胃溃疡(Gastric Ulcer GU)和胃癌(Gastrio Cancer Gc)均是我国乃至全世界人群中的常见病、多发病。近年来,虽然胃溃疡的发病率开始呈下降趋势,但仍属消化系统疾病中最常见的疾病之一,目前已被认为是癌前病变之一。据统计,5%左右的胃溃疡可发生癌变,甚至有统计最高达29.4%的胃癌来自胃溃疡[1]。在世界范围内恶性肿瘤中,胃癌位居第4,病死率位居第2,在我国则居第1位。胃癌发生的分子机制研究表明多基因变异是细胞发生癌变的内因[2]。各种癌基因、抑癌基因和错配修复基因、细胞信号传导通路的异常、细胞周期调控改变及相关产物均对胃癌的发生发展产生影响。如Survivin、DNA甲基化和CD44等均是近年来在胃癌组织中发现的并成为研究热点的基因。通过对Survivin、Dnmt和CD44三种基因在胃溃疡及胃癌中表达的差异的了解,有助于加深对胃癌发生、发展及转移机制的认识,更好的为临床应用中胃溃疡及胃癌的治疗提供理论依据和找到更好的治疗方法。 | 宋述安 王宁 赵志威 侯国伟 张哲男 姜涛 朴大勋 | 2015 | 现代生物医学进展2015，15，10： | 10 |
| 13 | MicroRNA Expression Signature in Gastric Cancer显示文摘Objective:To identify the miRNA specific signature as novel diagnostic and prognostic tools for gastric cancer. Methods:miRNAs expression profiling of 3 normal gastric tissues,24 malignant tissues,gastric cancer cell SGC7901 and normal gastric cell GES-1 were detected using microarray technology. The hierarchical clustering algorithm of the Cluster software was used to analyse the miRNAs expression of all samples. The expression levels of miR-433 and miR-9 which were significantly down-regulated in gastric cancer tissues and SGC7901 cells by microarray technology were validated by quantitative Real-time PCR(qRT-PCR). Results:Differential expressions of 26 individual miRNAs between normal samples(including 3 normal gastric tissues and GES-1 cells) and carcinomas(including 24 malignant tissues and SGC7901 cells) were discovered,19 of them showing down-regulation and 7 up-regulation in carcinoma samples. Hierarchical clustering of the cancer samples by their miRNA expression accurately separated the carcinomas from normal samples and further their histotypes of carcinomas. The expression levels of miR-433 and miR-9 were significantly down-regulated in gastric cancer tissues and SGC7901cells Conclusion:The differential expression of miR-433 and miR-9 may be used as a novel diagnostic tool for gastric cancer. | Hong-chun Luo Zhen-zhen Zhang Xia Zhang Bo Ning Jin-jun Guo Na Niel Bo Liu Xiao-ling Wu | 2009 | Chinese Journal of Cancer Research2009，21，1： | 9 |
| 14 | Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma显示文摘AIM: To investigate the aberrant methylation of CHFR promoter in human gastric cancer (GC) and its impact on the expression of CHFR mRNA and protein, as wel as its correlation with clinical and histological features of human GC. METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to detect the methylation status of CHFR promoter in 20 primary GC samples and paired normal gastric mucosa. The CHFR mRNA and protein expressions were investigated both by RT-PCR and by Western blotting. The CHFR protein expression in 39 GC samples was immunohistochemically examined. RESULTS: The DNA methylation of the CHFR gene was found in 9 of the 20 GC samples (45%) and the down-regulation of CHFR mRNA and protein was significantly associated with the methylation status of the CHFR gene (P = 0.006). In 20 samples of corresponding non-neoplastic mucosa, no DNA methylation of the CHFR gene was detected. The CHFR gene methylation in poorly differentiated GC sampleswas signifi cantly higher than that in well-differentiated GC samples (P = 0.014). Moreover, the negative CHFR protein expression rate in paraffin-embedded GC samples was 55.07% (38/69), the positive rate in poorly differentiated GC samples was 36.73% (18/49), which was signif icantly lower than 65.00% (13/20) in well-differentiated GC samples (χ2 = 4.586, P = 0.032). CONCLUSION: Aberrant methylation of the CHFR gene may be involved in the carcinogenesis and development of GC, and is the predominant cause of down-regulation or loss of CHFR mRNA or protein expression. As aberrant methylation of CHFR promoter is correlated with tumor differentiation, it may help to predict the prognosis of GC and CHFR may become a novel target of gene therapy for GC in the future. | Yu-Jia Gao Yan Xin lian-Jun Zhang Jin Zhou | 2008 | World Journal of Gastroenterology2008，14，32： | 9 |
| 15 | 鸟苷酸环化酶C和尾型同源盒转录因子2在胃癌及癌前病变组织中的表达及意义显示文摘目的研究鸟苷酸环化酶C(GC-C)和尾型同源盒转录因子2(CDX2)基因与蛋白在胃癌及癌前病变组织中的表达并探讨其临床意义。方法收集30例手术切除的胃癌及相应癌旁5cm胃黏膜组织,另32例非胃癌患者胃镜下取活检标本,其中23例肠上皮化生、9例异型增生。应用逆转录(RT)-PCR检测GC—C和CDX2 mRNA在胃癌及癌旁组织中的表达,Western印迹和间接免疫荧光组化技术检测GC—C和CDX2蛋白的表达,同时检测两者在肠上皮化生和异型增生中的表达。结果R-PCR显示GC-C和CDX2 mRNA在胃癌中的表达率分别为20/30和19/30,显著高于癌旁组织(0/30和0/30,P值均=0.000)。Western印迹检测GC-C和CDX2蛋白在胃癌组织中表达率分别为19/30和17/30,显著高于癌旁组织(0/30和0/30,P值均=0.000)。免疫荧光检测GC—C和CDX2在癌旁组织中不表达,在肠上皮化生组织中表达率为39.1%和39.1%、异型增生组织为55.6%和55.6%、胃癌组织为56.7%和60.0%,与癌旁组织间差异有统计学意义(P值均=0.000)。但在肠上皮化生、异型增生和胃癌间阳性率比较差异无统计学意义(P值均〉0.05)。两者在肠型胃癌中的表达高于弥漫型(P值分别=0.009和0.024),但与年龄、性别、病灶大小、临床病理分期、分化程度和淋巴结转移等因素无关(P值均〉0.05)。在肠上皮化生和胃癌中GC-C与CDX2的表达呈正相关(r分别=0.4524和0.3845,P分别=0.0371和0.0408)。结论GC—C和CDX2的异常表达与胃黏膜癌变的发生有关,可能参与人胃腺癌致癌过程的调节,检测GC-C与CDX2有助于早期胃癌和胃癌前病变诊断。 | 毛振彪 许钟 张健锋 朱慧君 章建国 潘正平 | 2008 | 中华消化杂志2008，28，10： | 9 |
| 16 | Precision medicine in gastric cancer显示文摘Gastric cancer(GC)is a complex disease linked to a series of environmental factors and unhealthy lifestyle habits,and especially to genetic alterations.GC represents the second leading cause of cancer-related deaths worldwide.Its onset is subtle,and the majority of patients are diagnosed once the cancer is already advanced.In recent years,there have been innovations in the management of advanced GC including the introduction of new classifications based on its molecular characteristics.Thanks to new technologies such as next-generation sequencing and microarray,the Cancer Genome Atlas and Asian Cancer Research Group classifications have also paved the way for precision medicine in GC,making it possible to integrate diagnostic and therapeutic methods.Among the objectives of the subdivision of GC into subtypes is to select patients in whom molecular targeted drugs can achieve the best results;many lines of research have been initiated to this end.After phase III clinical trials,trastuzumab,anti-Erb-B2 receptor tyrosine kinase 2(commonly known as ERBB2)and ramucirumab,anti-vascular endothelial growth factor receptor 2(commonly known as VEGFR2)monoclonal antibodies,were approved and introduced into first-and second-line therapies for patients with advanced/metastatic GC.However,the heterogeneity of this neoplasia makes the practical application of such approaches difficult.Unfortunately,scientific progress has not been matched by progress in clinical practice in terms of significant improvements in prognosis.Survival continues to be low in contrast to the reduction in deaths from many common cancers such as colorectal,lung,breast,and prostate cancers.Although several target molecules have been identified on which targeted drugs can act and novel products have been introduced into experimental therapeutic protocols,the overall approach to treating advanced stage GC has not substantially changed.Currently,surgical resection with adjuvant or neoadjuvant radiotherapy and chemotherapy are the most effective treatments for this disease.Future research should not underestimate the heterogeneity of GC when developing diagnostic and therapeutic strategies aimed toward improving patient survival. | Patrizia Bonelli Antonella Borrelli Franca Maria Tuccillo Lucrezia Silvestro Raffaele Palaia Franco Maria Buonaguro | 2019 | World Journal of Gastrointestinal Oncology2019，11，10： | 8 |
| 17 | hMLH1基因启动子CpG岛甲基化,微卫星不稳定与胃癌显示文摘由于胃癌预后的分子特征的作用还不清楚,本文旨在探讨hMLH1基因启动子CpG岛甲基化和微卫星不稳定(MSI)在胃癌预后的价值。我们对近年来关于hMLH1基因启动子CpG岛甲基化和微卫星不稳定(MSI)与胃癌关系的文献进行了综合分析。结果显示,MSI胃癌有着特殊临床病理学特征:老年女性,胃窦部位,肠型,较少浆膜侵犯,淋巴侵犯罕见,hMLH1基因启动子CpG岛甲基化,有较好的预后。因此可以得出结论,hMLH1基因启动子CpG岛甲基化和微卫星不稳定(MSI)在胃癌中有显著相关性,在胃癌早期发生、发展过程中起重要作用,对胃癌的鉴别诊断、预后评价、特殊临床干预具有重要的意义,可能成为胃癌早期诊断、评价预后、指导化疗的分子标志物。 | 闻旭阳 戴广海 | 2011 | 中国医药导报2011，8，7： | 8 |
| 18 | Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model显示文摘 | Wen LEI Hong-bin LIU Shi-bing WANG Xiu-mei ZHOU Shui-di ZHENG Ke-ni GUO Bu-yun MA Yu-Iong XIA Wen-song TAN Xin-yuan LIU Yi-gang WANG | 2013 | Acta Pharmacologica Sinica2013，34，4： | 8 |
| 19 | 甲状腺乳头状癌中Runx3基因mRNA和蛋白表达及其相关性显示文摘目的 探讨甲状腺乳头状癌(PTC)组织中Runt相关转录因子3(Runx3)基因mRNA和蛋白表达及意义.方法 采用反转录一聚合酶链反应(RT-PCR)和Western印迹技术,检测了67例PTC及其对应癌旁组织中Runx3基因mRNA及蛋白的表达.结果 Runx3 mRNA在PTC中的表达量相对值(0.31 ±0.07)低于癌旁甲状腺组织的表达量(0.92 ±0.08)(P〈0.05).Runx3基因mRNA的表达与患者的病理分级及淋巴结转移有关(P〈0.05).Runx3蛋白在PTC中的积分吸光度(A)值为(1012±221),明显低于癌旁组织的积分吸光度(A)值(1993±199)(P〈0.05).Runx3蛋白表达与患者的TNM分期、病理分级及淋巴结转移有关(P〈0.05).Runx3基因mRNA的表达与Runx3蛋白的表达有相关性(P〈0.05).结论 Runx3 mRNA及其蛋白在PTC表达均低于癌旁组织,Runx3基凶的表达异常在PTC的发生、发展中起着重要的作用. | 殷德涛 曹胜利 王勇飞 李红强 周玉冰 郑立运 江金花 王庆端 | 2011 | 中华医学杂志2011，91，20： | 7 |
| 20 | Methylation-mediated gene silencing as biomarkers of gastric cancer:a review显示文摘Despite a decline in the overall incidence of gastric cancer(GC),the disease remains the second most common cause of cancer-related death worldwide and is thus a significant global health problem.The best means of improving the survival of GC patients is to screen for and treat early lesions.However,GC is often diagnosed at an advanced stage and is associated with a poor prognosis.Current diagnostic and therapeutic strategies have not been successful in decreasing the global burden of the disease;therefore,the identification of reliable biomarkers for an early diagnosis,predictive markers of recurrence and survival and markers of drug sensitivity and/or resistance is urgently needed.The initiation and progression of GC depends not only on genetic alterations but also epigenetic changes,such as DNA methylation and histone modification.Aberrant DNA methylation is the most well-defined epigenetic change in human cancers and is associated with inappropriate gene silencing.Therefore,an increasing number of genes methylated at the promoter region have been targeted as possible biomarkers for different purposes,including early detection,classification,the assessment of the tumor prognosis,the development of therapeutic strategies and patient follow-up.This review article summarizes the current understanding and recent evidence regarding DNA methylation markers in GC with a focus on the clinical potential of these markers. | Jun Nakamura Tomokazu Tanaka Yoshihiko Kitajima Hirokazu Noshiro Kohji Miyazaki | 2014 | World Journal of Gastroenterology2014，20，34： | 7 |
您所在的机构暂未开通此部分的功能，请联系管理员